Thyroid and androgen receptor signaling are antagonized by
mu-Crystallin in prostate cancer

J 2021

Thyroid and androgen receptor signaling are antagonized by mu-Crystallin in prostate cancer

AKSOY, O., J. PENCIK, M. HARTENBACH, A.A. MOAZZAMI, M. SCHLEDERER et. al.

Basic information

Original name

Thyroid and androgen receptor signaling are antagonized by mu-Crystallin in prostate cancer

Authors

AKSOY, O., J. PENCIK, M. HARTENBACH, A.A. MOAZZAMI, M. SCHLEDERER, T. BALBER, A. VARADY, C. PHILIPPE, P.A. BALTZER, B. MAZUMDER, J.B. WHITCHURCH, C.J. ROBERTS, A. HAITEL, M. HERAC, M. SUSANI, M. MITTERHAUSER, R. MARCULESCU, J. STANGL-KREMSER, M.R. HASSLER, G. KRAMER, S.F. SHARIAT, Suzanne Dawn TURNER (826 United Kingdom of Great Britain and Northern Ireland, belonging to the institution), Boris TICHÝ (203 Czech Republic, belonging to the institution), Jan OPPELT (203 Czech Republic, belonging to the institution), Šárka POSPÍŠILOVÁ (203 Czech Republic, belonging to the institution), S. HARTENBACH, S. TANGERMANN, G. EGGER, H.A. NEUBAUER, R. MORIGGL, Z. CULIG, G. GREINER, G. HOERMANN, M. HACKER, D.M. HEERY, O. MERKEL and L. KENNER

Edition

International journal of cancer, HOBOKEN, International Union Against Cancer, 2021, 0020-7136

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

30204 Oncology

Country of publisher

Netherlands

Confidentiality degree

není předmětem státního či obchodního tajemství

References:

URL

Impact factor

Impact factor: 7.316

RIV identification code

RIV/00216224:14740/21:00121917

Organization unit

Central European Institute of Technology

DOI

http://dx.doi.org/10.1002/ijc.33332

UT WoS

000582971700001

Keywords in English

μ ‐ Crystallin; androgen receptor; prostate cancer; PSMA‐ PET; thyroid hormone receptor

Abstract

V originále

Androgen deprivation therapy (ADT) remains a key approach in the treatment of prostate cancer (PCa). However, PCa inevitably relapses and becomes ADT resistant. Besides androgens, there is evidence that thyroid hormone thyroxine (T4) and its active form 3,5,3 '-triiodo-L-thyronine (T3) are involved in the progression of PCa. Epidemiologic evidences show a higher incidence of PCa in men with elevated thyroid hormone levels. The thyroid hormone binding protein mu-Crystallin (CRYM) mediates intracellular thyroid hormone action by sequestering T3 and blocks its binding to cognate receptors (TR alpha/TR beta) in target tissues. We show in our study that low CRYM expression levels in PCa patients are associated with early biochemical recurrence and poor prognosis. Moreover, we found a disease stage-specific expression of CRYM in PCa. CRYM counteracted thyroid and androgen signaling and blocked intracellular choline uptake. CRYM inversely correlated with [18F]fluoromethylcholine (FMC) levels in positron emission tomography/magnetic resonance imaging of PCa patients. Our data suggest CRYM as a novel antagonist of T3- and androgen-mediated signaling in PCa. The role of CRYM could therefore be an essential control mechanism for the prevention of aggressive PCa growth.

Links

LQ1601, research and development project

Name: CEITEC 2020 (Acronym: CEITEC2020)

Investor: Ministry of Education, Youth and Sports of the CR

90132, large research infrastructures

Name: NCMG II

Citovat

AKSOY, O., J. PENCIK, M. HARTENBACH, A.A. MOAZZAMI, M. SCHLEDERER, T. BALBER, A. VARADY, C. PHILIPPE, P.A. BALTZER, B. MAZUMDER, J.B. WHITCHURCH, C.J. ROBERTS, A. HAITEL, M. HERAC, M. SUSANI, M. MITTERHAUSER, R. MARCULESCU, J. STANGL-KREMSER, M.R. HASSLER, G. KRAMER, S.F. SHARIAT, Suzanne Dawn TURNER, Boris TICHÝ, Jan OPPELT, Šárka POSPÍŠILOVÁ, S. HARTENBACH, S. TANGERMANN, G. EGGER, H.A. NEUBAUER, R. MORIGGL, Z. CULIG, G. GREINER, G. HOERMANN, M. HACKER, D.M. HEERY, O. MERKEL and L. KENNER. Thyroid and androgen receptor signaling are antagonized by mu-Crystallin in prostate cancer. International journal of cancer. HOBOKEN: International Union Against Cancer, 2021, vol. 148, No 3, p. 731-747. ISSN 0020-7136. Available from: https://dx.doi.org/10.1002/ijc.33332.

@article{1781883,
   author = {Aksoy, O. and Pencik, J. and Hartenbach, M. and Moazzami, A.A. and Schlederer, M. and Balber, T. and Varady, A. and Philippe, C. and Baltzer, P.A. and Mazumder, B. and Whitchurch, J.B. and Roberts, C.J. and Haitel, A. and Herac, M. and Susani, M. and Mitterhauser, M. and Marculescu, R. and StanglandKremser, J. and Hassler, M.R. and Kramer, G. and Shariat, S.F. and Turner, Suzanne Dawn and Tichý, Boris and Oppelt, Jan and Pospíšilová, Šárka and Hartenbach, S. and Tangermann, S. and Egger, G. and Neubauer, H.A. and Moriggl, R. and Culig, Z. and Greiner, G. and Hoermann, G. and Hacker, M. and Heery, D.M. and Merkel, O. and Kenner, L.},
   article_location = {HOBOKEN},
   article_number = {3},
   doi = {http://dx.doi.org/10.1002/ijc.33332},
   keywords = {μ ‐ Crystallin; androgen receptor; prostate cancer; PSMA‐ PET; thyroid hormone receptor},
   language = {eng},
   issn = {0020-7136},
   journal = {International journal of cancer},
   title = {Thyroid and androgen receptor signaling are antagonized by mu-Crystallin in prostate cancer},
   url = {https://onlinelibrary.wiley.com/doi/10.1002/ijc.33332},
   volume = {148},
   year = {2021}
}

TY  - JOUR
ID  - 1781883
AU  - Aksoy, O. - Pencik, J. - Hartenbach, M. - Moazzami, A.A. - Schlederer, M. - Balber, T. - Varady, A. - Philippe, C. - Baltzer, P.A. - Mazumder, B. - Whitchurch, J.B. - Roberts, C.J. - Haitel, A. - Herac, M. - Susani, M. - Mitterhauser, M. - Marculescu, R. - Stangl-Kremser, J. - Hassler, M.R. - Kramer, G. - Shariat, S.F. - Turner, Suzanne Dawn - Tichý, Boris - Oppelt, Jan - Pospíšilová, Šárka - Hartenbach, S. - Tangermann, S. - Egger, G. - Neubauer, H.A. - Moriggl, R. - Culig, Z. - Greiner, G. - Hoermann, G. - Hacker, M. - Heery, D.M. - Merkel, O. - Kenner, L.
PY  - 2021
TI  - Thyroid and androgen receptor signaling are antagonized by mu-Crystallin in prostate cancer
JF  - International journal of cancer
VL  - 148
IS  - 3
SP  - 731-747
EP  - 731-747
PB  - International Union Against Cancer
SN  - 00207136
KW  - μ ‐ Crystallin
KW  - androgen receptor
KW  - prostate cancer
KW  - PSMA‐ PET
KW  - thyroid hormone receptor
UR  - https://onlinelibrary.wiley.com/doi/10.1002/ijc.33332
N2  - Androgen deprivation therapy (ADT) remains a key approach in the treatment of prostate cancer (PCa). However, PCa inevitably relapses and becomes ADT resistant. Besides androgens, there is evidence that thyroid hormone thyroxine (T4) and its active form 3,5,3 '-triiodo-L-thyronine (T3) are involved in the progression of PCa. Epidemiologic evidences show a higher incidence of PCa in men with elevated thyroid hormone levels. The thyroid hormone binding protein mu-Crystallin (CRYM) mediates intracellular thyroid hormone action by sequestering T3 and blocks its binding to cognate receptors (TR alpha/TR beta) in target tissues. We show in our study that low CRYM expression levels in PCa patients are associated with early biochemical recurrence and poor prognosis. Moreover, we found a disease stage-specific expression of CRYM in PCa. CRYM counteracted thyroid and androgen signaling and blocked intracellular choline uptake. CRYM inversely correlated with [18F]fluoromethylcholine (FMC) levels in positron emission tomography/magnetic resonance imaging of PCa patients. Our data suggest CRYM as a novel antagonist of T3- and androgen-mediated signaling in PCa. The role of CRYM could therefore be an essential control mechanism for the prevention of aggressive PCa growth.
ER  -

AKSOY, O., J. PENCIK, M. HARTENBACH, A.A. MOAZZAMI, M. SCHLEDERER, T. BALBER, A. VARADY, C. PHILIPPE, P.A. BALTZER, B. MAZUMDER, J.B. WHITCHURCH, C.J. ROBERTS, A. HAITEL, M. HERAC, M. SUSANI, M. MITTERHAUSER, R. MARCULESCU, J. STANGL-KREMSER, M.R. HASSLER, G. KRAMER, S.F. SHARIAT, Suzanne Dawn TURNER, Boris TICHÝ, Jan OPPELT, Šárka POSPÍŠILOVÁ, S. HARTENBACH, S. TANGERMANN, G. EGGER, H.A. NEUBAUER, R. MORIGGL, Z. CULIG, G. GREINER, G. HOERMANN, M. HACKER, D.M. HEERY, O. MERKEL and L. KENNER. Thyroid and androgen receptor signaling are antagonized by mu-Crystallin in prostate cancer. \textit{International journal of cancer}. HOBOKEN: International Union Against Cancer, 2021, vol.~148, No~3, p.~731-747. ISSN~0020-7136. Available from: https://dx.doi.org/10.1002/ijc.33332.

Detailed Information on Publication Record